Prevention of thrombosis in patients on hemodialysis by low-dose aspirin

N Engl J Med. 1979 Sep 13;301(11):577-9. doi: 10.1056/NEJM197909133011103.


Since platelet cyclo-oxygenase is much more sensitive to inactivation by aspirin than is the enzyme in the arterial wall and low doses of aspirin may prevent thrombosis by blocking thromboxane synthesis, we conducted a randomized, double-blind trial of aspirin (160 mg per day) vs. placebo in 44 patients on chronic hemodialysis. The study was continued until there were 24 patients with thrombi and both groups had been under observation for a mean of nearly five months. Thrombi occurred in 18 of 25 (72 per cent) of patients given placebo and 16 of 19 (32 per cent) of those given aspirin (P less than 0.01). The incidence of thrombosis was reduced from 0.46 thrombi per patient month in the placebo group to 0.16 thrombi per patient month in the aspirin group (p less than 0.005). A dose of 160 mg of aspirin per day is an effective, nontoxic antithrombotic regimen in patients on hemodialysis.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acetylation
  • Adult
  • Arteriovenous Shunt, Surgical / adverse effects
  • Aspirin / administration & dosage*
  • Aspirin / pharmacology
  • Aspirin / therapeutic use
  • Blood Platelets / enzymology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prostaglandin-Endoperoxide Synthases / blood
  • Renal Dialysis / adverse effects*
  • Sex Factors
  • Thrombosis / enzymology
  • Thrombosis / epidemiology
  • Thrombosis / prevention & control*
  • Time Factors


  • Prostaglandin-Endoperoxide Synthases
  • Aspirin